湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. （2025 年第二次临时会议） 湖南方盛制药股份有限公司（以下简称"公司"）第六届董事会 独立董事专门会议 2025 年第二次临时会议于 2025 年 5 月 29 日以通讯 表决的方式召开。会议通知及会议材料已于 2025 年 5 月 27 日以电子 邮件、微信、电话等方式通知全体独立董事。本次会议由独立董事袁 雄先生召集并主持，会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议参与表决人数及召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。会议审议并通过了《关于对控 股子公司增资暨关联交易的议案》： 本次对广东方盛融科药业有限公司（以下简称"方盛融科"）增 资将有效充实方盛融科药品研发项目的资金实力，将进一步增强方盛 融科研发投入的可持续性，能够在一定程度上分担公司的新品研发投 入及研发风险，不存在损害中小股东利益的情形，符合有关法律法规、 规范性文件和《公司章程》等的有关规定。 湖南方盛制药股份有限公司 第六届董事会独立董事专门会议决议 综上，我们同意《关于对控股子公 ...

Core Viewpoint - Shenzhen New Star (603978.SZ) is enhancing its subsidiary's capital structure by introducing a local state-owned investment fund, aiming to improve competitiveness and operational support for its subsidiary, Luoyang New Star [1][7]. Group 1: Capital Increase and Structure - Luoyang New Star plans to raise 200 million yuan through a capital increase, with the registered capital increasing from 1 billion to 1.184 billion yuan, reducing Shenzhen New Star's ownership from 100% to 84.47% while maintaining control [1][3]. - The investment fund, Gongkong New Star Fund, is established with contributions from Shenzhen New Star and local state-owned assets, with a total subscription of 500 million yuan planned [4]. Group 2: Financial Performance and Commitments - Luoyang New Star achieved revenues of 2.423 billion yuan and a net profit of 6.9914 million yuan in 2024, with a performance commitment of a cumulative net profit of no less than 77 million yuan from 2025 to 2027 [2][6]. - Shenzhen New Star reported revenues of 2.563 billion yuan in 2024, but incurred a net loss of 291 million yuan, marking three consecutive years of losses totaling approximately 480 million yuan [2][9]. Group 3: Business Segments and Challenges - Shenzhen New Star operates in three main segments: aluminum grain refiners, battery aluminum foil materials, and lithium hexafluorophosphate, with Luoyang New Star being crucial for the battery aluminum foil segment [1][7]. - The lithium hexafluorophosphate segment faced significant challenges due to low market prices and increased competition, leading to a loss of 42.3482 million yuan in 2024 [8].